Pfizer says EMA lifts warning on its smoking cessation drug Champix
pharmafile | May 24, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing |Â Â Champix, EMA, Pfizer, anti-smoking, drug trialÂ
US pharma giant Pfizer (NYSE: PFE) said the European Medicines Agency has lifted a warning on its anti-smoking drug Champix (varenicline) following a study showing the therapy did not appear to increase the risk of neuropsychiatric side effects.
Champix is approved as an effective therapy for aiding smokers quit however, the European Medicines Agency added a black triangle warning following reports linking it to agitation, aggression, panic, anxiety, depression and suicidal thoughts.
The warning required additional safety monitoring for people taking the drug.
Rory O’Connor, Pfizer’s chief medical officer, said: “The new safety and efficacy information in the European label further supports the importance of Champix as a treatment option for healthcare providers and for those who are trying to quit smoking.”
Pfizer said the European regulators adopted a decision to change the label in the light of reassuring results from a large study, published in The Lancet in April.
Pfizer’s medicine, which has been prescribed to millions of patients around the world, also carries a black box warning in the US relating to neuropsychiatric adverse events.
Chantix was approved by the US Food and Drug Administration in May 2006 as a prescription medication that helps to stop smoking.
Anjali Shukla
Related Content

AstraZeneca’s Trixeo approved in EU for asthma in patients aged 12 and over
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved by the European Commission as a …

Sobi’s olezarsen recommended for EU approval in severe hypertriglyceridaemia
Sobi’s olezarsen (TRYNGOLZA) has received a positive opinion from the European Medicines Agency’s Committee for …

EMA selects TrialAssure anonymisation platform for clinical trial documents
TrialAssure has announced that its ANONYMIZE platform has been selected by the European Medicines Agency …






